Azurity Pharmaceuticals
Azurity Pharmaceuticals is seeking a Program Manager, Enablement in the Enterprise Program Management Office (EPMO). The role supports enterprise enablement leaders by driving day-to-day program management for cross-functional initiatives across the Medical Office, Science Office, and CBIO, while serving as an advocate for Azurity’s Management System and standard ways of working. The position focuses on enabling collaboration, ensuring visibility on progress, risks, and dependencies, and translating leadership direction into actionable next steps.
Headquarters
Woburn, Massachusetts, United States
Company Size
501-1000 employees
Founded
2000
Azurity Pharmaceuticals is a privately held specialty pharmaceutical company committed to delivering innovative, high-quality medicines for overlooked patients. The company offers a diversified portfolio of 50+ branded medicines spanning 10 dosage forms and 10 key therapeutic areas, with a global footprint in over 50 countries. Azurity leverages a Next-Gen Commercial Model powered by data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement.
Formulation specialist Azurity to lay off 75 amid plans to sunset Massachusetts plant
Jul 14, 2025
Mass. drugmaker to close manufacturing facility, lay off 75 workers
Jul 11, 2025
QHP Capital runs single-asset CV process for pharma company – updated
Jun 6, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Azurity Pharmaceuticals.
Azurity Pharmaceuticals didn’t post a salary, so this is our estimate from similar listings.
67% above the average for this role
PATENT—Fed. Cir.: Alkem’s vancomycin oral solution did not infringe Azurity’s liquid antibiotic formulation patent
Apr 8, 2025